Nomura Holdings
CYTK icon

Nomura Holdings’s Cytokinetics CYTK Stock Holding History

Nomura Holdings’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$272K Sell
4,130
-62,077
-94% -$3.95M ﹤0.01% 1510
2025
Q4 		$4.21M Sell
66,207
-41,046
-38% -$2.55M 0.01% 832
2025
Q3 		$5.89M Buy
107,253
+83,943
+360% +$3.46M 0.01% 703
2025
Q2 		$770K Sell
23,310
-5,222
-18% -$182K ﹤0.01% 1051
2025
Q1 		$1.15M Sell
28,532
-37,249
-57% -$1.71M ﹤0.01% 1235
2024
Q4 		$3.09M Sell
65,781
-81,185
-55% -$4.22M ﹤0.01% 936
2024
Q3 		$7.76M Buy
146,966
+25,012
+21% +$1.39M 0.02% 514
2024
Q2 		$6.61M Buy
121,954
+20,345
+20% +$1.23M 0.01% 591
2024
Q1 		$7.12M Buy
+101,609
New +$7.86M 0.02% 534
2021
Q4 		– Sell
-800
Closed -$29K – 2279
2021
Q3 		$29K Buy
+800
New +$23.6K ﹤0.01% 1879
2014
Q4 		– Sell
-20,000
Closed -$70K – 2364
2014
Q3 		$70K Buy
+20,000
New +$84K ﹤0.01% 2589
2014
Q2 		– Sell
-10,209
Closed -$97K – 2791
2014
Q1 		$97K Buy
+10,209
New +$92.3K ﹤0.01% 2509

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Nomura Holdings's CYTK Position: Q1 2026 in Review

Nomura Holdings reduced its Cytokinetics (CYTK) stake by 94% in Q1 2026, selling an estimated $3.95M and leaving 4,130 shares worth $272K. The position accounts for ﹤0.01% of the portfolio, ranked #1510.

Nomura Holdings first reported a position in CYTK in Q1 2014 and has held it in 12 quarters since. The position peaked at $7.76M in Q3 2024. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Nomura Holdings held 4,130 shares of Cytokinetics worth $272K as of Q1 2026.
  • Nomura Holdings sold 62,077 Cytokinetics shares in Q1 2026, an estimated $3.95M.
  • Cytokinetics made up ﹤0.01% of Nomura Holdings's portfolio in Q1 2026, its #1510 holding.
  • Nomura Holdings first reported a position in Cytokinetics in Q1 2014 and has held it in 12 quarters since.
  • Nomura Holdings's Cytokinetics position peaked at $7.76M in Q3 2024.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Nomura Holdings's 13F filing for Q1 2026, filed 15 May 2026.